Expression of phosphorylated Stat3, cyclin D1 and Bcl-xL in extramammary Paget disease
- PMID: 16634897
- DOI: 10.1111/j.1365-2133.2005.06951.x
Expression of phosphorylated Stat3, cyclin D1 and Bcl-xL in extramammary Paget disease
Abstract
Background: Stat3 (Signal transducer and activator of transcription-3) is an oncogene that plays a critical role in regulating fundamental processes associated with malignant transformation and cell survival. It participates in oncogenesis through upregulation of genes encoding apoptosis inhibitors (Bcl-xL) and cell cycle regulators (cyclin D1). The expression of Stat3, Bcl-xL and cyclin D1 protein has not been investigated in extramammary Paget disease (EMPD).
Objectives: To study the expression of phosphorylated Stat3 (p-Stat3), Bcl-xL and cyclin D1 protein in EMPD and to evaluate the relationships among them.
Methods: Thirty-six tissue samples from 34 patients with primary EMPD were subjected to immunohistochemical staining for p-Stat3, cyclin D1 and Bcl-xL.
Results: Thirty-five of 36 specimens were clearly positive for p-Stat3 in EMPD, while 30 of 36 and 32 of 36 were positive for cyclin D1 and Bcl-xL expression, respectively. In all of four invasive EMPD specimens, strong and frequent expression of these three molecules was evident; moreover, two invasive EMPD specimens with lymph nodal metastasis showed very strong nuclear and membranous p-Stat3 staining. Two metastatic lymph node specimens showed very strong nuclear and local membrane p-Stat3 staining. There were significant correlations between p-Stat3 and cyclin D1 expression and between p-Stat3 and Bcl-xL expression.
Conclusions: Our study shows that the expression of p-Stat3, cyclin D1 and Bcl-xL may play a pivotal role in the pathogenesis of EMPD.
Similar articles
-
Expression of the p38 MAPK, NF-kappaB and cyclin D1 in extramammary Paget's disease.J Dermatol Sci. 2007 Mar;45(3):187-92. doi: 10.1016/j.jdermsci.2006.12.003. Epub 2007 Jan 5. J Dermatol Sci. 2007. PMID: 17207971
-
Expression of insulin-like growth factor-1 receptor, p-AKT and p-ERK1/2 protein in extramammary Paget's disease.Br J Dermatol. 2006 Sep;155(3):586-91. doi: 10.1111/j.1365-2133.2006.07366.x. Br J Dermatol. 2006. PMID: 16911286
-
Concordant over-expression of transcription factor Sp1 and vascular endothelial growth factor in extramammary Paget's disease.Int J Dermatol. 2008 Jun;47(6):562-6. doi: 10.1111/j.1365-4632.2008.03643.x. Int J Dermatol. 2008. PMID: 18477144
-
Risk stratification in extramammary Paget disease.Clin Exp Dermatol. 2015 Jul;40(5):473-8. doi: 10.1111/ced.12690. Epub 2015 May 26. Clin Exp Dermatol. 2015. PMID: 26011765 Review.
-
Polyphenolic molecules targeting STAT3 pathway for the treatment of cancer.Life Sci. 2021 Mar 1;268:118999. doi: 10.1016/j.lfs.2020.118999. Epub 2021 Jan 6. Life Sci. 2021. PMID: 33421525 Review.
Cited by
-
Inhibition of signal transducer and activator of transcription 3 expression by RNA interference suppresses invasion through inducing anoikis in human colon cancer cells.World J Gastroenterol. 2008 Jan 21;14(3):428-34. doi: 10.3748/wjg.14.428. World J Gastroenterol. 2008. PMID: 18200666 Free PMC article.
-
Prognostic Factors of Extramammary Paget's Disease.Curr Treat Options Oncol. 2018 Aug 15;19(10):47. doi: 10.1007/s11864-018-0567-4. Curr Treat Options Oncol. 2018. PMID: 30112691 Review.
-
Microarray-based identification of differentially expressed genes in extramammary Paget's disease.Int J Clin Exp Med. 2015 May 15;8(5):7251-60. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26221264 Free PMC article.
-
CDK4: A Novel Therapeutic Target for Extramammary Paget's Disease.Front Oncol. 2021 Jul 29;11:710378. doi: 10.3389/fonc.2021.710378. eCollection 2021. Front Oncol. 2021. PMID: 34395284 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous